drugset / Trial / NCT00210899

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

NCT00210899

Phase 3 Completed 828 enrolled Basilea Pharmaceutica
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections. The study will also characterize the safety and tolerability of treatment with ceftobiprole medocaril in patients with complicated skin and skin structure infections.

Timeline

Start
2005-09
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ceftazidime Small molecule 1 g
Subject Ceftobiprole medocaril Small molecule 500 mg
Comparator Vancomycin Other / unclassified 1 g